Clinical Trial

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a interventional phase II study aiming to examine the complete response rate of a bortezomib-based salvage regimen in adults with refractory or relapsed acute lymphoblastic leukemia (ALL), seeking to compare outcomes with the available literature and with our historical data on relapsed/refractory ALL.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-12; most recent amendment 2025-05-13.
Status change: Not Yet Recruiting → Recruiting 2024-03-19
Trial Details
NCT Number NCT06034561
Lead Sponsor Instituto do Cancer do Estado de São Paulo
Collaborators: Libbs Farmacêutica LTDA
Conditions Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
Enrollment 50 participants
Start Date 2024-04-01
Primary Completion 2028-08 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2025-05-16